We have located links that may give you full text access.
Journal Article
Meta-Analysis
Systematic Review
A Systematic Review and Meta-Analysis of Molecular Biomarkers Associated with Early Neurological Deterioration Following Acute Stroke.
BACKGROUND: Early neurological deterioration (END) following acute stroke is associated with poorer long-term outcomes. Identification of patients at risk could assist early monitoring and treatment decisions. This review summarised the evidence describing non-radiological biomarkers for END.
SUMMARY: Electronic searches from January 1990 to March 2017 identified studies reporting a blood/cerebrospinal fluid (CSF)/urine biomarker measurement within 24 h of acute stroke and at least 2 serial assessments of clinical neurological status (< 24 h and < 7 days). Out of 12,895 citations, 82 studies were included, mostly focusing on ischaemic stroke. Using higher neurological thresholds, the n-weighted END incidence for ischaemic stroke was 11.9% (95% CI 11.4-12.4%) and 18.6% (17.9-19.2%) for lower thresholds. Incidence decreased with advancing study publication year (Pearson r-squared 0.23 and 0.15 for higher and lower threshold studies). After classification into 3 broad categories, meta-analysis showed that biomarkers associated with increased END risk (n; fixed-effects mean difference; 95% CI) were "metabolic" (glucose [n = 9,481; 0.90 mmol/L; 0.74-1.06], glycosylated haemoglobin [n = 3,146; 0.33%; 0.19-0.46], low-density lipoprotein [n = 4,839; 0.13 mmol/L; 0.06-0.21], total cholesterol [n = 4,762; 0.21 mmol/L; 0.11-0.31], triglycerides [n = 4,820; 0.11 mmol/L; 0.06-0.17], urea [n = 1,351; 0.55 mmol/L; 0.14-0.96], decreasing albumin [n = 513; 0.33 g/dL; 0.05-0.61]); "inflammatory and excitotoxic" (plasma glutamate [n = 688; 60.13 µmol/L; 50.04-70.22], CSF glutamate [n = 369; 7.50 µmol/L; 6.76-8.23], homocysteine [n = 824; 2.15 µmol/L; 0.68-3.61], leucocytes [n = 3,766; 0.54 × 109/L; 0.34-0.74], high-sensitivity C-reactive protein [n = 1,707; 3.79 mg/L; 1.23-6.35]); and "coagulation/haematological" (fibrinogen [n = 3,132; 0.32 g/L; 0.25-0.40]; decreasing haemoglobin [n = 3,586; 2.38 g/L; 0.15-4.60]). Key Messages: Declining incidence of END may represent improving care standards; however, it remains a frequent occurrence. Although statistical associations exist between biomarkers and an increased risk of END, the most promising still need prospective evaluation to determine their additional value relative to baseline radiological and clinical characteristics.
SUMMARY: Electronic searches from January 1990 to March 2017 identified studies reporting a blood/cerebrospinal fluid (CSF)/urine biomarker measurement within 24 h of acute stroke and at least 2 serial assessments of clinical neurological status (< 24 h and < 7 days). Out of 12,895 citations, 82 studies were included, mostly focusing on ischaemic stroke. Using higher neurological thresholds, the n-weighted END incidence for ischaemic stroke was 11.9% (95% CI 11.4-12.4%) and 18.6% (17.9-19.2%) for lower thresholds. Incidence decreased with advancing study publication year (Pearson r-squared 0.23 and 0.15 for higher and lower threshold studies). After classification into 3 broad categories, meta-analysis showed that biomarkers associated with increased END risk (n; fixed-effects mean difference; 95% CI) were "metabolic" (glucose [n = 9,481; 0.90 mmol/L; 0.74-1.06], glycosylated haemoglobin [n = 3,146; 0.33%; 0.19-0.46], low-density lipoprotein [n = 4,839; 0.13 mmol/L; 0.06-0.21], total cholesterol [n = 4,762; 0.21 mmol/L; 0.11-0.31], triglycerides [n = 4,820; 0.11 mmol/L; 0.06-0.17], urea [n = 1,351; 0.55 mmol/L; 0.14-0.96], decreasing albumin [n = 513; 0.33 g/dL; 0.05-0.61]); "inflammatory and excitotoxic" (plasma glutamate [n = 688; 60.13 µmol/L; 50.04-70.22], CSF glutamate [n = 369; 7.50 µmol/L; 6.76-8.23], homocysteine [n = 824; 2.15 µmol/L; 0.68-3.61], leucocytes [n = 3,766; 0.54 × 109/L; 0.34-0.74], high-sensitivity C-reactive protein [n = 1,707; 3.79 mg/L; 1.23-6.35]); and "coagulation/haematological" (fibrinogen [n = 3,132; 0.32 g/L; 0.25-0.40]; decreasing haemoglobin [n = 3,586; 2.38 g/L; 0.15-4.60]). Key Messages: Declining incidence of END may represent improving care standards; however, it remains a frequent occurrence. Although statistical associations exist between biomarkers and an increased risk of END, the most promising still need prospective evaluation to determine their additional value relative to baseline radiological and clinical characteristics.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app